Pharmaceutical companies encounter substantial obstacles when developing new antidepressants due to issues like high placebo responses, depression's diverse nature, and reliance on subjective assessments. This has led to a 99% failure rate in clinical trials, with just 18 FDA-approved drugs in the past decade from substantial R&D investments, leaving over 38% of those with depression without effective treatments and contributing to financial losses for patients and the industry, worsened by factors like patent expiration and declining revenues. Brainify.AI employs patented AI technology, based on over 13.5 million training segments, utilizing Deep Convolutional Neural Networks (DCNNs) and Generative Adversarial Networks (GANs), which are hardware-independent and validated on clinical trial data, revolutionizing precision psychiatry and depression diagnostics. Their leadership team boasts a Harvard-educated CEO, a COO with a successful tech exit, renowned data scientists, and a prestigious scientific board.
What is the problem?
Pharmaceutical companies face significant challenges when introducing new antidepressants, such as high placebo response rates, the complex nature of depression, and reliance on subjective questionnaires rather than objective biomarkers. As a result, there has been a 99% failure rate in clinical trials, with only 18 FDA-approved drugs in the last decade emerging from $100B massive R&D investments. Over 38% of the depressed population lacks effective treatment options. Issues like patent exclusivity loss and declining revenues further exacerbate the situation, leading to financial losses for both patients and the industry.
What is their solution?
Brainify.AI is a precision psychiatry biomarker platform that improves the likelihood of new drug approval and increases the efficacy of the drug. Brainify.AI products are designed to enhance the efficiency of clinical trials and improve patient outcomes. Featuring products PlaceboInsight AI, TherapyInsight AI, assist in identifying the best patients for clinical trials. PlaceboInsight AI identifies placebo responders during Phase 2 and Phase 3, and TherapyInsight AI predicts treatment response for Phase 3 trials using Phase 2 data. TherapyInsight AI serves as a Companion Diagnostics (CDx) for the specific treatment to increase the treatment efficacy by identifying patients who will benefit the most.
